Cytotheryx, Inc. is a preclinical cell therapy company leveraging proprietary technology to address acute, chronic, and rare genetic liver diseases. A Mayo Clinic spinout, Cytotheryx has developed a differentiated platform that enables the scalable production of clinically relevant, fully functional primary human hepatocytes for therapeutic use.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/26 | $60,000,000 | Series A |
QRS Investments | undisclosed |
